The board of directors of Simulations Plus Inc (Nasdaq:SLP) declared the company's next ongoing quarterly dividend of USD0.06 per share of its common stock, it disclosed on Monday.

This cash dividend is due on 1 November 2019 to shareholders of record as of 25 October 2019.

Simulations Plus is a drug discovery and software company that provides both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease.

In addition, the company's software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.